← Human Trials & Peer-Reviewed Studies
The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
Plain-language guide to PMID 17205144 (2006): single-blind randomized controlled trial of Angiotensin II Type 1 Receptor Blockers in 40 patients.
Key Facts
- PMID
- 17205144
- Journal
- Journal of gastrointestinal and liver diseases : JGLD
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Fierbinteanu-Braticevici C et al. (7 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II Type 1 Receptor Blockers, published as a randomized controlled trial.
The aim of the study was to assess the effects of valsartan, a new generation angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in cirrhosis.
Who Took Part
The study group was 40 patients.
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
All the patients had hemodynamic, endocrine and renal parameters measured on day 0 and 7.
How the Study Was Run
In design terms this was a randomized, single-blind and placebo-controlled study.
The patients were allocated by chance, so the Angiotensin II Type 1 Receptor Blockers group and the comparison group should start out alike.
In this single-blind Angiotensin II Type 1 Receptor Blockers study one party knew the assignments and the other did not.
Some patients received a placebo instead of Angiotensin II Type 1 Receptor Blockers, giving a reference point.
The following were assessed: creatinine clearance, lithium clearance, plasma renin activity, concentration of plasma aldosteron and sodium homeostasis.
Hemodynamic effects were assessed sonographically by portal flow volume and velocity evaluation, and mean arterial blood pressure.
What Was Measured
Topics PubMed links to this paper include Aldosterone, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Biomarkers, Creatinine, Hemodynamics and Hypertension, Portal.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Angiotensin II Type 1 Receptor Blockers in 40 patients.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2006 (Journal of gastrointestinal and liver diseases : JGLD), a journal based in Romania.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.